Business Context and Reporting Period
This Form 8-K, dated July 11, 2025, is filed by Helix Acquisition Corp. II (the "Company" or "Helix") regarding its business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics or "BBOT"). The filing announces that the Registration Statement on Form S-4 for the transaction has been declared effective by the U.S. Securities and Exchange Commission (SEC) on July 10, 2025. Upon closing, the combined entity will be renamed "BridgeBio Oncology Therapeutics" (PubCo).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures for either Helix or BBOT. This document serves as a regulatory notification of the transaction status rather than a financial performance report.
Material Changes and Transaction Status
- SEC Approval: The Form S-4 Registration Statement was declared effective by the SEC on July 10, 2025.
- Shareholder Vote: The business combination is subject to shareholder approval. The definitive Proxy Statement/Prospectus will be mailed to Helix shareholders of record as of June 30, 2025.
- Transaction Structure: The deal involves Helix, BBOT, and Helix II Merger Sub., a wholly-owned subsidiary of Helix, pursuant to a Business Combination Agreement dated February 28, 2025 (as amended June 17, 2025).
Guidance, Outlook, and Risks
Management commentary focuses on the anticipated closing of the business combination and the future development of BBOT's product candidates. Key forward-looking elements and risks include:
- Clinical Trials: Expectations regarding the timing and data readouts for the ONKORAS-101 and BREAKER-101 trials, as well as the expected dosing of the first patient with BBO-11818.
- Product Pipeline: Potential therapeutic benefits of candidates BBO-8520, BBO-10203, and BBO-11818.
- Financial Runway: Expectations regarding the proceeds from the business combination and BBOT's expected cash runway.
- Material Risks: Risks include the inability to consummate the transaction, regulatory delays, shareholder redemption requests, uncertainty of clinical trial outcomes, intellectual property claims, and the ability to secure raw materials.
Investor Verification Checklist
- Verify the final vote results from Helix shareholders regarding the business combination.
- Review the definitive Proxy Statement/Prospectus for detailed financial projections and terms of the merger.
- Monitor the volume of redemption requests from Helix public shareholders, which could impact the combined company's cash position.
- Track the status of regulatory approvals for BBOT's product candidates, specifically ONKORAS-101 and BREAKER-101.
- Confirm the actual closing date of the transaction and the final capitalization of the new entity.